Chaperone nanobodies protect gelsolin against MT1-MMP degradation and alleviate amyloid burden in the gelsolin amyloidosis mouse model

Molecular Therapy

Volumn 22, Issue 10, 2014, Pages 1768-1778

  Van Overbeke, Wouter ^a   Verhelle, Adriaan ^a   Everaert, Inge ^a   Zwaenepoel, Olivier ^a   Vandekerckhove, Joël ^a   Cuvelier, Claude ^a   Derave, Wim ^a   Gettemans, Jan ^a  

^a GHENT UNIVERSITY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; GELSOLIN; GELSOLIN NANOBODY; MATRIX METALLOPROTEINASE 14; NANOBODY; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; CHAPERONE; PEPTIDE; PROTEIN BINDING;

AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SPECIFICITY; ENDOMYSIUM; ENZYME DEGRADATION; GELSOLIN AMYLOIDOSIS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUSCLE CONTRACTILITY; NONHUMAN; PROTECTION; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; DISEASE MODEL; FAMILIAL AMYLOIDOSIS; HUMAN; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROTEIN DEGRADATION; PROTEIN DOMAIN; SKELETAL MUSCLE;

MUS; MUS MUSCULUS;

AMYLOID; AMYLOIDOSIS; AMYLOIDOSIS, FAMILIAL; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY SPECIFICITY; DISEASE MODELS, ANIMAL; GELSOLIN; HUMANS; MATRIX METALLOPROTEINASE 14; MICE; MOLECULAR CHAPERONES; MUSCLE FIBERS, SKELETAL; PEPTIDES; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEOLYSIS; SINGLE-DOMAIN ANTIBODIES;

EID: 84926143267     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.132     Document Type: Article

References (47)

1. Sunde, M, Serpell, LC, Bartlam, M, Fraser, PE, Pepys, MB and Blake, CC (1997). Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J Mol Biol 273: 729-739.
2. Westermark, P (2005). Aspects on human amyloid forms and their fibril polypeptides. FEBS J 272: 5942-5949.
3. Harrison, RS, Sharpe, PC, Singh, Y and Fairlie, DP (2007). Amyloid peptides and proteins in review. Rev Physiol Biochem Pharmacol 159: 1-77.
4. de la Chapelle, A, Tolvanen, R, Boysen, G, Santavy, J, Bleeker-Wagemakers, L, Maury, CP, et al. (1992). Gelsolin-derived familial amyloidosis caused by asparagine or tyrosine substitution for aspartic acid at residue 187. Nature genetics 2: 157-160.
5. Meretoja, J (1973). Genetic aspects of familial amyloidosis with corneal lattice dystrophy and cranial neuropathy. Clin Genet 4: 173-185.
6. Ghoshdastider, U, Popp, D, Burtnick, LD and Robinson, RC (2013). The expanding superfamily of gelsolin homology domain proteins. Cytoskeleton (Hoboken) 70: 775-795.
7. Kwiatkowski, DJ, Stossel, TP, Orkin, SH, Mole, JE, Colten, HR and Yin, HL (1986). Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature 323: 455-458.
8. Grazi, E, Magri, E, Cuneo, P and Cataldi, A (1991). The control of cellular motility and the role of gelsolin. FEBS Lett 295: 163-166.
9. Bucki, R, Levental, I, Kulakowska, A and Janmey, PA (2008). Plasma gelsolin: function, prognostic value, and potential therapeutic use. Curr Protein Pept Sci 9: 541-551.
10. Burtnick, LD, Urosev, D, Irobi, E, Narayan, K and Robinson, RC (2004). Structure of the N-terminal half of gelsolin bound to actin: roles in severing, apoptosis and FAF. EMBO J 23: 2713-2722.
11. Robinson, RC, Choe, S and Burtnick, LD (2001). The disintegration of a molecule: the role of gelsolin in FAF, familial amyloidosis (Finnish type). Proc Natl Acad Sci USA 98: 2117-2118.
12. Chen, CD, Huff, ME, Matteson, J, Page, L, Phillips, R, Kelly, JW et al. (2001). Furin initiates gelsolin familial amyloidosis in the Golgi through a defect in Ca(2+) stabilization. EMBO J 20: 6277-6287.
13. Page, LJ, Suk, JY, Huff, ME, Lim, HJ, Venable, J, Yates, J et al. (2005). Metalloendoprotease cleavage triggers gelsolin amyloidogenesis. EMBO J 24: 4124-4132.
14. Kiuru-Enari, S and Haltia, M (2013). Hereditary gelsolin amyloidosis. Handb Clin Neurol 115: 659-681.
15. Pihlamaa, T, Rautio, J, Kiuru-Enari, S and Suominen, S (2011). Gelsolin amyloidosis as a cause of early aging and progressive bilateral facial paralysis. Plast Reconstr Surg 127: 2342-2351.
16. Carrwik, C and Stenevi, U (2009). Lattice corneal dystrophy, gelsolin type (Meretoja's syndrome). Acta Ophthalmol 87: 813-819.
17. Page, LJ, Suk, JY, Bazhenova, L, Fleming, SM, Wood, M, Jiang, Y et al. (2009). Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins. Proc Natl Acad Sci USA 106: 11125-11130.
18. Hamers-Casterman, C, Atarhouch, T, Muyldermans, S, Robinson, G, Hamers, C, Songa, EB et al. (1993). Naturally occurring antibodies devoid of light chains. Nature 363: 446-448.
19. Vanlandschoot, P, Stortelers, C, Beirnaert, E, Ibañez, LI, Schepens, B, Depla, E et al. (2011). Nanobodies®: new ammunition to battle viruses. Antiviral Res 92: 389-407.
20. Van Impe, K, Bethuyne, J, Cool, S, Impens, F, Ruano-Gallego, D, De Wever, O et al. (2013). A nanobody targeting the F-Actin capping protein CapG restrains breast cancer metastasis. Breast Cancer Res 15: R116.
21. De Clercq, S, Boucherie, C, Vandekerckhove, J, Gettemans, J and Guillabert, A (2013). L-plastin nanobodies perturb matrix degradation, podosome formation, stability and lifetime in THP-1 macrophages. PLoS ONE 8: e78108.
22. De Clercq, S, Zwaenepoel, O, Martens, E, Vandekerckhove, J, Guillabert, A and Gettemans, J (2013). Nanobody-induced perturbation of LFA-1/L-plastin phosphorylation impairs MTOC docking, immune synapse formation and T cell activation. Cell Mol Life Sci 70: 909-922.
23. Van Audenhove, I, Boucherie, C, Pieters, L, Zwaenepoel, O, Vanloo, B, Martens, E et al. (2014). Stratifying fascin and cortactin function in invadopodium formation using inhibitory nanobodies and targeted subcellular delocalization. FASEB J 28: 1805-1818.
24. Van Audenhove, I, Van Impe, K, Ruano-Gallego, D, De Clercq, S, De Muynck, K, Vanloo, B et al. (2013). Mapping cytoskeletal protein function in cells by means of nanobodies. Cytoskeleton (Hoboken) 70: 604-622.
25. Itoh, Y and Seiki, M (2006). MT1-MMP: a potent modifier of pericellular microenvironment. J Cell Physiol 206: 1-8.
26. Sternlicht, MD and Werb, Z (2001). How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17: 463-516.
27. Yu, FX, Johnston, PA, Südhof, TC and Yin, HL (1990). gCap39, a calcium ion-And polyphosphoinositide-regulated actin capping protein. Science 250: 1413-1415.
28. Burtnick, LD, Koepf, EK, Grimes, J, Jones, EY, Stuart, DI, McLaughlin, PJ et al. (1997). The crystal structure of plasma gelsolin: implications for actin severing, capping, and nucleation. Cell 90: 661-670.
29. Solomon, JP, Yonemoto, IT, Murray, AN, Price, JL, Powers, ET, Balch, WE et al. (2009). The 8 and 5 kDa fragments of plasma gelsolin form amyloid fibrils by a nucleated polymerization mechanism, while the 68 kDa fragment is not amyloidogenic. Biochemistry 48: 11370-11380.
30. Van den Abbeele, A, De Clercq, S, De Ganck, A, De Corte, V, Van Loo, B, Soror, SH et al. (2010). A llama-derived gelsolin single-domain antibody blocks gelsolin-G-Actin interaction. Cell Mol Life Sci 67: 1519-1535.
31. Cortez-Retamozo, V, Lauwereys, M, Hassanzadeh Gh, G, Gobert, M, Conrath, K, Muyldermans, S et al. (2002). Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 98: 456-462.
32. Dennis, MS, Zhang, M, Meng, YG, Kadkhodayan, M, Kirchhofer, D, Combs, D et al. (2002). Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 277: 35035-35043.
33. Muyldermans, S (2013). Nanobodies: natural single-domain antibodies. Annu Rev Biochem 82: 775-797.
34. Francis, GL (2010). Albumin and mammalian cell culture: implications for biotechnology applications. Cytotechnology 62: 1-16.
35. Howie, AJ and Brewer, DB (2009). Optical properties of amyloid stained by Congo red: history and mechanisms. Micron 40: 285-301.
36. Williams, SC (2013). Small nanobody drugs win big backing from pharma. Nat Med 19: 1355-1356.
37. Dixon, FJ, Maurer, PH and Deichmiller, MP (1953). Half-lives of homologous serum albumins in several species. Proc Soc Exp Biol Med 83: 287-288.
38. Vincke, C, Loris, R, Saerens, D, Martinez-Rodriguez, S, Muyldermans, S and Conrath, K (2009). General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem 284: 3273-3284.
39. Huang, Y and Mucke, L (2012). Alzheimer mechanisms and therapeutic strategies. Cell 148: 1204-1222.
40. Yu, YJ, Zhang, Y, Kenrick, M, Hoyte, K, Luk, W, Lu, Y et al. (2011). Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 3: 84ra44.
41. Li, T, Bourgeois, JP, Celli, S, Glacial, F, Le Sourd, AM, Mecheri, S et al. (2012). Cell-penetrating anti-GFAP VHH and corresponding fluorescent fusion protein VHH-GFP spontaneously cross the blood-brain barrier and specifically recognize astrocytes: application to brain imaging. FASEB J 26: 3969-3979.
42. Rutgers, KS, Nabuurs, RJ, van den Berg, SA, Schenk, GJ, Rotman, M, Verrips, CT et al. (2011). Transmigration of beta amyloid specific heavy chain antibody fragments across the in vitro blood-brain barrier. Neuroscience 190: 37-42.
43. Caljon, G, Caveliers, V, Lahoutte, T, Stijlemans, B, Ghassabeh, GH, Van Den Abbeele, J et al. (2012). Using microdialysis to analyse the passage of monovalent nanobodies through the blood-brain barrier. Br J Pharmacol 165: 2341-2353.
44. Towbin, H, Staehelin, T and Gordon, J (1992). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979. Biotechnology 24: 145-149.
45. Woskowicz, AM, Weaver, SA, Shitomi, Y, Ito, N and Itoh, Y (2013). MT-LOOPdependent localization of membrane type I matrix metalloproteinase (MT1-MMP) to the cell adhesion complexes promotes cancer cell invasion. J Biol Chem 288: 35126-35137.
46. Pasquato, A, Dettin, M, Basak, A, Gambaretto, R, Tonin, L, Seidah, NG et al. (2007). Heparin enhances the furin cleavage of HIV-1 gp160 peptides. FEBS Lett 581: 5807-5813.
47. Everaert, I, Stegen, S, Vanheel, B, Taes, Y and Derave, W (2013). Effect of beta-Alanine and carnosine supplementation on muscle contractility in mice. Med Sci Sports Exerc 45: 43-51.